Italia markets closed

XORTX Therapeutics Inc. (XRTX)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,9300+0,3400 (+13,13%)
Alla chiusura: 04:00PM EDT
2,8600 -0,07 (-2,39%)
Dopo ore: 07:35PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,5900
Aperto2,7500
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,5301 - 3,0000
Intervallo di 52 settimane1,9800 - 67,7160
Volume25.146
Media Volume49.663
Capitalizzazione8,637M
Beta (5 anni mensile)-0,15
Rapporto PE (ttm)N/D
EPS (ttm)-3,6000
Prossima data utili15 mag 2024 - 20 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A12,14
  • GlobeNewswire

    XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

    ISS, a leading proxy advisory firm, recommends XORTX Therapeutics Inc.’s shareholders vote FOR the share consolidation resolution, stating that approving the share consolidation will “enhance the long-term growth prospects of the Company by broadening its financing alternatives.”Shareholders who have questions or need assistance with voting their shares voting should contact XORTX’s strategic advisor and proxy solicitation agent, Laurel Hill Advisory Group, by telephone at 1-877-452-7184 or by e

  • GlobeNewswire

    XORTX Calls Special Meeting of Shareholders

    CALGARY, Alberta, Oct. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company has called a special meeting of shareholders for 10:00 a.m. (Calgary time) on October 25, 2023 (the “Meeting”). Materials for the Meeting have been mailed to shareholders and are available on the Com

  • GlobeNewswire

    XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023

    CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology (the “ASN”). The abstract entitled "The Effect of Lowering Uric Acid with a Xanthine Oxidase Inhibitor on PKD in Mice” was r